A- A A+

Australien. New heroin treatment option yielding positive results among patients at Melbourne injecting rooms

(…) The injectable is a slow-release version of buprenorphine available for patients to take once a week, once a month, or in Summer's case, once every six weeks.

(…)

It found 45 per cent of people weren't using opioids illicitly in the last week of the trial, week 24, compared to 2 per cent of those on placebo.

Dr Clark began prescribing and administering it to patients at the injecting room who were suitable and open to treatment at no cost. (abc.net, Australien, 15.06.2021)

https://www.abc.net.au/news/2021-06-15/new-heroin-treatment-helping-patients-in-melbourne/100197558

Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. 

Kosten T, Aharonovich E, Nangia N, Zavod A, Akerman SC, Lopez-Bresnahan M, Sullivan MA. 

Addict Behav. 2020 Dec;111:106538. doi: 10.1016/j.addbeh.2020.106538. Epub 2020 Jul 3. PMID: 32777606.

https://www.sciencedirect.com/science/article/pii/S0306460320306687

Emergency physician perspectives on initiating buprenorphine/naloxone in the emergency department: A qualitative study. 

Dong KA, Lavergne KJ, Salvalaggio G, Weber SM, Xue CJ, Kestler A, Kaczorowski J, Orkin AM, Pugh A, Hyshka E. 

J Am Coll Emerg Physicians Open. 2021 Apr 29;2(2):e12409. doi: 10.1002/emp2.12409. PMID: 33969340; PMCID: PMC8082712.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082712/

Buprenorphine: Far Beyond the "Ceiling".

Infantino R, Mattia C, Locarini P, Pastore AL, Maione S, Luongo L. 

Biomolecules. 2021 May 31;11(6):816. doi: 10.3390/biom11060816. PMID: 34072706.

https://www.mdpi.com/2218-273X/11/6/816

Extended-Release Buprenorphine and Its Evaluation With Patient-Reported Outcomes. 

Compton WM, Volkow ND. 

JAMA Netw Open. 2021 May 3;4(5):e219708. doi: 10.1001/jamanetworkopen.2021.9708. PMID: 33970262.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779757

Prevalence and Characteristics of Chronic Pain in Buprenorphine and Methadone-Maintained Patients. 

Delorme J, Pennel L, Brousse G, Daulouède JP, Delile JM, Lack P, Gérard A, Dematteis M, Kabore JL, Authier N, Chenaf C; TOXIDOL Study group. 

Front Psychiatry. 2021 Apr 26;12:641430. doi: 10.3389/fpsyt.2021.641430. PMID: 33981257; PMCID: PMC8107279.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107279/

Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study. 

Tay Wee Teck J, Baldacchino A, Gibson L, Lafferty C. 

Front Pharmacol. 2021 Mar 23;12:631784. doi: 10.3389/fphar.2021.631784. PMID: 33833682; PMCID: PMC8021866.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021866/

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. 

De Aquino JP, Parida S, Sofuoglu M. 

Clin Drug Investig. 2021 Apr 5:1–12. doi: 10.1007/s40261-021-01032-7. Epub ahead of print. PMID: 33818748; PMCID: PMC8020374.

https://pubmed.ncbi.nlm.nih.gov/33818748/

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. 

Lintzeris N, Dunlop AJ, Haber PS, et al. 

JAMA Netw Open. 2021;4(5):e219041. doi:10.1001/jamanetworkopen.2021.9041

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779751

Australien. ‘Game changer’ treatment cuts heroin use

An opioid treatment being introduced around Australia has been dubbed a game changer after dozens of users at Melbourne’s safe injecting room stopped taking heroin.

The Richmond site was among the first in Australia to provide depot buprenorphine, a slow-release injection given weekly or monthly, outside clinical trials after it was approved for use in September 2019. (Sydney Morning Herald, Australien, 10.05.2021)

https://www.theage.com.au/national/victoria/game-changer-treatment-cuts-heroin-use-20210505-p57p2i.html

Poisoning Deaths Associated With Buprenorphine Almost Always Involve Sedatives or Other Opioids

Buprenorphine has a favorable safety profile because of its partial agonist and ceiling respiratory depression effects. However, there are poisoning deaths associated with it. Researchers used data from autopsies of sudden and unexpected deaths in Finland, which has high rates of illicit buprenorphine use, to investigate the extent to which these deaths were associated with the use of other substances. In Finland, all sudden and unexpected deaths (12% of all deaths in this study period) are investigated with autopsy, including comprehensive toxicology in 75%. (Alcohol, Other Drugs, and Health: Current Evidence, USA, März-April 2021)

http://www.bu.edu/aodhealth/2021/04/29/poisoning-deaths-associated-with-buprenorphine-almost-always-involve-sedatives-or-other-opioids/

Sixmo: Buprenorphin-6-Monatsimplantat erhält Zulassungsempfehlung 

Das Buprenorphin-haltige 6-Monatsimplantat Sixmo hat eine Zulassungsempfehlung für die Substitutionstherapie von stabilen Opiatabhängigen mit einem maximalen Buprenorphin-Bedarf von 8 mg/Tag erhalten. (Gelbe Liste, 16.05.2021)

https://www.gelbe-liste.de/nachrichten/sixmo-buprenorphin-implantat-zulassungsempfehlung

EMA. Sixmo (Buprenorphin) - Übersicht über Sixmo und warum es in der EU zugelassen ist

Was ist Sixmo und wofür wird es angewendet?

Sixmo ist ein Implantat, das zur Behandlung einer Abhängigkeit von Opioiden wie Heroin oder Morphin angewendet wird. Es enthält den Wirkstoff Buprenorphin.Sixmo wird bei Erwachsenen angewendet, die bereits stabil sind und Buprenorphin unter der Zunge (höchstens 8 mg/Tag) anwenden und außerdem medizinische, soziale und psychologische Behandlung erhalten. (EMA – European Medicine Agency 2019)

https://www.ema.europa.eu/en/documents/overview/sixmo-epar-overview_de.pdf

Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. 

Larance B, Degenhardt L, Grebely J, Nielsen S, Bruno R, Dietze P, Lancaster K, Larney S, Santo T Jr, Shanahan M, Memedovic S, Ali R, Farrell M. 

Addiction. 2020 Jul;115(7):1295-1305. doi: 10.1111/add.14941. Epub 2020 Feb 5. PMID: 31860767; PMCID: PMC7292758.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292758/

Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence. 

Hard B. 

Case Rep Psychiatry. 2021 Feb 27;2021:6657350. doi: 10.1155/2021/6657350. PMID: 33728083; PMCID: PMC7936910.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936910/

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. 

Fava M, Thase ME, Trivedi MH, Ehrich E, Martin WF, Memisoglu A, Nangia N, Stanford AD, Yu M, Pathak S. 

Mol Psychiatry. 2020 Jul;25(7):1580-1591. doi: 10.1038/s41380-018-0284-1. Epub 2018 Oct 29. PMID: 30374191; PMCID: PMC7303008.

https://www.nature.com/articles/s41380-018-0284-1

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route. 

Kharidia, J., Howgate, E.M., Laffont, C.M., Liu, Y. and Young, M.A. (2021), 

Clinical Pharmacology in Drug Development. doi.org/10.1002/cpdd.934

https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.934

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis. 

McCormack L, Ponce J, Chatterjee A, Tan JK. 

JAAD Case Rep. 2021 Jan 11;10:22-24. doi: 10.1016/j.jdcr.2020.12.031. PMID: 33732840; PMCID: PMC7941000.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941000/

Micro-dosing Intravenous Buprenorphine to Rapidly Transition From Full Opioid Agonists. 

Thakrar AP, Jablonski L, Ratner J, Rastegar DA. 

J Addict Med. 2021 Mar 19. doi: 10.1097/ADM.0000000000000838. Epub ahead of print. PMID: 33758112.

Abstract

https://pubmed.ncbi.nlm.nih.gov/33758112/

SUBOXONE® Sublingualfilm ist jetzt für die Behandlung der Opioidabhängigkeit verfügbar

Mannheim - Indivior (INDV) gab heute bekannt, dass Suboxone® Sublingualfilm (Buprenorphin und Naloxon) jetzt in Deutschland für die Substitutionstherapie bei Opioidabhängigkeit im Rahmen medizinischer, sozialer und psychotherapeutischer Maßnahmen verfügbar ist. Suboxone wird angewendet bei Erwachsenen und Jugendlichen über 15 Jahren, die einer Suchtbehandlung zugestimmt haben.

Das Medikament enthält Buprenorphin, einen partiellen Opioid-Agonisten, und Naloxon, einen Opioid-Antagonisten, und wird unter die Zunge (sublingual) platziert oder an die Innenseite einerWange (buccal) gelegt, und dort belassen, bis er sich vollständig aufgelöst hat. (Indivior, Pressemitteilung, 12.03.2021)

PM_Indivior_Suboxone Sublingualfilm_03_2021

The administration of the opioid buprenorphine decreases motivational error signals

D.M. Pfabigan, M. Rütgen, S.L. Kroll, I. Riečanský, C. Lamm,

Psychoneuroendocrinology, 2021, 105199, ISSN 0306-4530, doi.org/10.1016/j.psyneuen.2021.105199. In Press, Journal Pre-proof

https://www.sciencedirect.com/science/article/pii/S0306453021000731

RBP-6000: a rationally designed prolonged-release buprenorphine formulation

Authors: Wiest K., Shaya G., Somaini L., and Greenwald M.

Summary: Background. RBP-6000 (Sublocade®; Subutex Prolonged Release Solution for Injection®) is a monthly prolonged-release subcutaneous formulation of buprenorphine that has been rationally designed to achieve sustained mu-opioid receptor (MOR) occupancy at levels that suppress withdrawal symptoms, drug-liking and craving, which drive addiction

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, January 18, 2021

https://www.heroinaddictionrelatedclinicalproblems.org/download-article.php?idarticolodoi=Adoi0000310

Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. 

Wong JSH, Nikoo M, Westenberg JN, Suen JG, Wong JYC, Krausz RM, Schütz CG, Vogel M, Sidhu JA, Moe J, Arishenkoff S, Griesdale D, Mathew N, Azar P. 

Addict Sci Clin Pract. 2021 Feb 12;16(1):11. doi: 10.1186/s13722-021-00220-2. PMID: 33579359; PMCID: PMC7881636. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881636/

Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence. 

Robbins JL, Englander H, Gregg J. 

J Am Board Fam Med. 2021 Feb;34(Suppl):S141-S146. doi: 10.3122/jabfm.2021.S1.200236. PMID: 33622829.

https://www.jabfm.org/content/34/Supplement/S141.long

Opioid overdose reduced in patients taking buprenorphine

Study indicates the drug is effective in opioid users who also take benzodiazepines for anxiety, other conditions. (Washington University School of Medicine, 02.03.2021)

https://medicine.wustl.edu/news/buprenorphine-protects-against-opioid-overdoses-even-in-benzodiazepine-users/

Suchtrehabilitation von Opioidabhängigen in Behandlung mit injizierbarem, subkutanem Depot-Buprenorphin (ARIDE) - Addiction recovery of opioid dependent patients treated with injectable subcutaneous depot buprenorphine (ARIDE)

Wir freuen uns über Ihr Interesse an der ARIDE-Studie, die unter Leitung von Herrn Prof. Jens Reimer und Dr. Bernd Schulte durch das Zentrum für Interdisziplinäre Suchtforschung der Universität Hamburg (ZIS) durchgeführt wird. 

Sie finden auf diesen Seiten Informationen zum Ablauf der Studie sowohl in kompakter Form als auch das ausführliche Studienprotokoll und weitergehende Hintergrundinformationen.

https://www.aride-studie.de/

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. 

Rolland B, Trojak B, Nourredine M, Bachellier J, Chappuy M, Bendimerad P, Kosim M, Hjelmström P, Meroueh F, Nubukpo P, Brousse G. 

Drug Alcohol Depend. 2021 Mar 1;220:108492. doi: 10.1016/j.drugalcdep.2020.108492. Epub 2021 Jan 8. PMID: 33482572.

https://www.sciencedirect.com/science/article/pii/S0376871620306578

Intravenous Buprenorphine Micro-dosing Induction in a Patient on Methadone Treatment: A Case Report. 

Crane K, Snead J, Stanley R, Avery J, Ghosh SM, Mints G. 

Psychosomatics. 2020 Jul 25:S0033-3182(20)30213-9. doi: 10.1016/j.psym.2020.07.004. Epub ahead of print. PMID: 33451853; PMCID: PMC7381397.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381397/

Microdosing and standard-dosing take-home buprenorphine from the emergency department: A feasibility study. 

Moe J, Badke K, Pratt M, Cho RY, Azar P, Flemming H, Sutherland KA, Harvey B, Gurney L, Lockington J, Brasher P, Gill S, Garrod E, Bath M, Kestler A. 

J Am Coll Emerg Physicians Open. 2020 Oct 20;1(6):1712-1722. doi: 10.1002/emp2.12289. PMID: 33392580; PMCID: PMC7771760.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771760/

Effectiveness of incentivised adherence and abstinence monitoring in buprenorphine maintenance: a pragmatic, randomised controlled trial. 

Elarabi, H. F., Shawky, M., Mustafa, N., Radwan, D., Elarasheed, A., Yousif Ali, A., Osman, M., Kashmar, A., Al Kathiri, H., Gawad, T., Kodera, A., Al Jneibi, M., Adem, A., Lee, A. J., and Marsden, J. (2021) 

Addiction, doi.org/10.1111/add.15394. 

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15394